CJ Pharmaceutical

HK inno.N, formerly known as CJ Healthcare, is a leading South Korean pharmaceutical and bio-health company. Originally established in 1984 as the pharmaceutical division of the CJ Group conglomerate, it was acquired by Kolmar Korea in 2018 and rebranded in 2020. The company is best known for developing K-CAB (tegoprazan), a first-in-class potassium-competitive acid blocker (P-CAB) that has become a global blockbuster for gastrointestinal disorders. Beyond its core gastroenterology franchise, HK inno.N maintains a diverse portfolio of vaccines, oncology treatments, and health beverages, including the market-leading hangover relief drink 'Condition'. The company is currently focused on expanding its global footprint and advancing a high-value pipeline in cell and gene therapies and targeted oncology.